Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Gould Rothberg BE, Bracken MB, Rimm DL.

J Natl Cancer Inst. 2009 Apr 1;101(7):452-74. doi: 10.1093/jnci/djp038. Epub 2009 Mar 24. Review.

2.

Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.

Jamieson NB, Carter CR, McKay CJ, Oien KA.

Clin Cancer Res. 2011 May 15;17(10):3316-31. doi: 10.1158/1078-0432.CCR-10-3284. Epub 2011 Mar 28. Review.

3.

Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis.

Mocellin S, Hoon DS, Pilati P, Rossi CR, Nitti D.

J Clin Oncol. 2007 Apr 20;25(12):1588-95. Review.

PMID:
17443001
4.

Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies.

Schramm SJ, Mann GJ.

Mol Cancer Ther. 2011 Aug;10(8):1520-8. doi: 10.1158/1535-7163.MCT-10-0901. Epub 2011 Jun 9. Review.

5.

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

Mocellin S, Pasquali S, Rossi CR, Nitti D.

J Natl Cancer Inst. 2010 Apr 7;102(7):493-501. doi: 10.1093/jnci/djq009. Epub 2010 Feb 23. Review.

6.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

7.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

8.

Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases.

de Boer M, van Dijck JA, Bult P, Borm GF, Tjan-Heijnen VC.

J Natl Cancer Inst. 2010 Mar 17;102(6):410-25. doi: 10.1093/jnci/djq008. Epub 2010 Feb 26. Review.

9.

Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction.

Palmieri G, Ascierto PA, Perrone F, Satriano SM, Ottaiano A, Daponte A, Napolitano M, Caracò C, Mozzillo N, Melucci MT, Cossu A, Tanda F, Gallo C, Satriano RA, Castello G.

J Clin Oncol. 2003 Mar 1;21(5):767-73. Review. Erratum in: J Clin Oncol. 2003 May 15;21(10):2048.

PMID:
12610172
10.

Biomarkers in melanoma.

Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R.

Ann Oncol. 2009 Aug;20 Suppl 6:vi8-13. doi: 10.1093/annonc/mdp251. Review.

11.

CD56+ lymphoma with skin involvement: clinicopathologic features and classification.

Gniadecki R, Rossen K, Ralfkier E, Thomsen K, Skovgaard GL, Jønsson V.

Arch Dermatol. 2004 Apr;140(4):427-36. Review.

PMID:
15096371
12.

Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.

Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N.

Cancer. 2006 Apr 1;106(7):1431-42. Review.

13.

Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.

Chen M, Huang J, Zhu Z, Zhang J, Li K.

BMC Cancer. 2013 Nov 11;13:539. doi: 10.1186/1471-2407-13-539. Review. Erratum in: BMC Cancer. 2014;14:892.

14.

Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis.

Zhao L, Yu N, Guo T, Hou Y, Zeng Z, Yang X, Hu P, Tang X, Wang J, Liu M.

Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1047-54. doi: 10.1158/1055-9965.EPI-13-0696. Epub 2014 Mar 17. Review.

15.

Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.

Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM.

J Clin Oncol. 2015 Mar 1;33(7):773-81. doi: 10.1200/JCO.2014.57.4756. Epub 2015 Jan 20. Review.

PMID:
25605840
16.

Construction and analysis of multiparameter prognostic models for melanoma outcome.

Rothberg BE, Rimm DL.

Methods Mol Biol. 2014;1102:227-58. doi: 10.1007/978-1-62703-727-3_13. Review.

17.

Biomarkers in laryngeal dysplasia: a systematic review.

Nankivell P, Weller M, McConkey C, Paleri V, Mehanna H.

Head Neck. 2011 Aug;33(8):1170-6. doi: 10.1002/hed.21592. Epub 2010 Nov 17. Review.

PMID:
21755560
18.

Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis.

Ruys AT, Groot Koerkamp B, Wiggers JK, Klümpen HJ, ten Kate FJ, van Gulik TM.

Ann Surg Oncol. 2014 Feb;21(2):487-500. doi: 10.1245/s10434-013-3286-x. Epub 2013 Oct 1. Review.

PMID:
24081803
19.

Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines.

Mallett S, Timmer A, Sauerbrei W, Altman DG.

Br J Cancer. 2010 Jan 5;102(1):173-80. doi: 10.1038/sj.bjc.6605462. Epub 2009 Dec 8. Review.

20.

Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review.

Diaz-Padilla I, Amir E, Marsh S, Liu G, Mackay H.

Gynecol Oncol. 2012 Feb;124(2):354-65. doi: 10.1016/j.ygyno.2011.10.034. Epub 2011 Nov 6. Review.

PMID:
22063461
Items per page

Supplemental Content

Write to the Help Desk